Latest News
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
1 September 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for neurodegenerative diseases, announced on Monday a redesigned development plan for PrimeC in amyotrophic lateral ...
Prasco increases Ohio pharmaceutical footprint
1 September 2026 - Prasco LLC, a pharmaceutical commercialisation company specialising in authorised generics, today announced on Monday the acquisition of a strategically located distribution facility in Carey, Ohio.Prasco said that the 130,000+ squ...
UCB agrees with US government to lower medicine costs and strengthen US manufacturing
1 September 2026 - Belgium-based biopharmaceutical company UCB (EBR:UCB) announced on Monday that it has reached an an agreement with the US government that will continue to support patient access to important medicines while enabling significant inv...
BioArctic and Eisai announce final positive recommendation from Canada's Drug Agency supporting public reimbursement of Leqembi
1 September 2026 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Tuesday that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public r...
Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis
31 August 2026 - US pharmaceutical company Karyopharm Therapeutics Inc. (NASDAQ: KPTI) said on Monday it has submitted a supplemental New Drug Application to the US Food and Drug Administration for Accelerated Approval of XPOVIO (selinexor) combined ...